You are here
JFDA authorises emergency use of Pfizer's COVID-19 oral Paxlovid pill
By JT - Feb 03,2022 - Last updated at Feb 03,2022
AMMAN — The Jordan Food and Drug Administration (JFDA) has granted an emergency use authorisation (EUA) for Pfizer's COVID-19 oral Paxlovid pill.
JFDA Director-General Nizar Mhiedat on Thursday said that EUA was declared after the administration’s technical committees evaluated the safety of the medication and favourable results were shown, the Jordan News Agency, Petra, reported.
Used to treat mild-to-moderate COVID infection in adults above 18 years, Paxlovid comprises 100 mg ritonavir and 150 mg nirmatrelvir.
Paxlovid is available by prescription only, and it is not recommended during pregnancy, and breastfeeding should be interrupted during treatment.
Related Articles
WASHINGTON — The US Food and Drug Administration (FDA) on Wednesday authorised Pfizer's COVID pill for high-risk people aged 12 and over, ca
WASHINGTON — Pfizer said on Tuesday that clinical trials confirmed its COVID pill — a new type of treatment that should withstand the mutati
WASHINGTON — Pfizer said on Friday that a clinical trial of its pill to treat COVID-19 had shown it is highly effective, hailing it is as a
Opinion
- Popular
- Rated
- Commented
Nov 13, 2024
Nov 13, 2024
Nov 13, 2024
Newsletter
Get top stories and blog posts emailed to you each day.
